3B Blackbio DX Ltd
Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products[1]
- Market Cap ₹ 1,360 Cr.
- Current Price ₹ 1,586
- High / Low ₹ 1,750 / 1,084
- Stock P/E 24.5
- Book Value ₹ 378
- Dividend Yield 0.32 %
- ROCE 25.5 %
- ROE 19.8 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company is expected to give good quarter
- Company's median sales growth is 21.9% of last 10 years
Cons
- Earnings include an other income of Rs.27.4 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of BSE Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19 | 17 | 16 | 23 | 23 | 29 | 227 | 81 | 62 | 74 | 96 | 142 | 153 | |
| 18 | 16 | 14 | 18 | 16 | 20 | 77 | 44 | 33 | 41 | 46 | 85 | 100 | |
| Operating Profit | 1 | 2 | 3 | 5 | 7 | 9 | 150 | 37 | 29 | 33 | 50 | 57 | 53 |
| OPM % | 7% | 9% | 16% | 23% | 31% | 32% | 66% | 46% | 47% | 44% | 52% | 40% | 35% |
| 0 | 0 | 0 | 0 | 1 | 2 | 3 | 7 | 7 | 13 | 15 | 26 | 27 | |
| Interest | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 6 |
| Profit before tax | 0 | 0 | 1 | 5 | 7 | 10 | 152 | 43 | 35 | 44 | 64 | 77 | 74 |
| Tax % | 23% | 23% | 19% | 24% | 25% | 23% | 25% | 26% | 27% | 28% | 25% | 22% | |
| 0 | 0 | 1 | 3 | 5 | 8 | 114 | 32 | 26 | 32 | 48 | 60 | 56 | |
| EPS in Rs | 0.36 | 0.51 | 1.76 | 5.35 | 8.18 | 10.24 | 151.66 | 42.89 | 34.55 | 37.40 | 55.57 | 68.27 | 64.70 |
| Dividend Payout % | 0% | 0% | 17% | 9% | 6% | 7% | 6% | 24% | 8% | 8% | 7% | 7% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | -9% |
| 3 Years: | 32% |
| TTM: | 54% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 68% |
| 5 Years: | -12% |
| 3 Years: | 31% |
| TTM: | 13% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 58% |
| 5 Years: | 26% |
| 3 Years: | 31% |
| 1 Year: | 12% |
| Return on Equity | |
|---|---|
| 10 Years: | 27% |
| 5 Years: | 18% |
| 3 Years: | 18% |
| Last Year: | 20% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 9 | 9 | 9 | 9 |
| Reserves | 4 | 4 | 5 | 12 | 16 | 25 | 125 | 146 | 185 | 214 | 260 | 316 |
| 8 | 8 | 9 | 6 | 6 | 4 | 2 | 3 | 2 | 1 | 0 | 3 | |
| 7 | 6 | 6 | 6 | 8 | 9 | 59 | 37 | 19 | 24 | 27 | 51 | |
| Total Liabilities | 25 | 24 | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 248 | 296 | 378 |
| 4 | 3 | 3 | 4 | 4 | 4 | 5 | 7 | 8 | 7 | 7 | 28 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 1 | 59 | 93 | 92 | 117 | 156 | 158 |
| 21 | 21 | 22 | 26 | 32 | 40 | 130 | 93 | 114 | 123 | 132 | 193 | |
| Total Assets | 25 | 24 | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 248 | 296 | 378 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 1 | 2 | 4 | 7 | 98 | 37 | 20 | 27 | 43 | 52 | |
| -0 | -0 | -0 | -1 | -1 | -1 | -70 | -28 | 15 | -20 | -33 | -24 | |
| -0 | -1 | -0 | 0 | -1 | 1 | -2 | -15 | -5 | -4 | -3 | -1 | |
| Net Cash Flow | -0 | 0 | 0 | 1 | 2 | 7 | 26 | -6 | 30 | 3 | 7 | 28 |
| Free Cash Flow | 0 | 1 | 0 | 1 | 3 | 6 | 96 | 35 | 18 | 26 | 42 | 27 |
| CFO/OP | 23% | 69% | 36% | 52% | 71% | 101% | 90% | 129% | 100% | 115% | 116% | 121% |
Ratios
Consolidated / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 262 | 283 | 321 | 259 | 290 | 252 | 56 | 136 | 200 | 179 | 138 | 129 |
| Inventory Days | 145 | 143 | 175 | 164 | 141 | 124 | 187 | |||||
| Days Payable | 218 | 203 | 186 | 69 | 66 | 28 | 70 | |||||
| Cash Conversion Cycle | 188 | 223 | 310 | 259 | 290 | 252 | 56 | 136 | 296 | 253 | 235 | 245 |
| Working Capital Days | 175 | 205 | 247 | 253 | 287 | 275 | 65 | 162 | 241 | 215 | 169 | 143 |
| ROCE % | 7% | 7% | 13% | 24% | 28% | 31% | 162% | 27% | 19% | 21% | 26% | 25% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Customers (MDx) Count |
|
||||||||||
| Number of Countries of Global Presence Count |
|||||||||||
| Export Sales (Non-COVID) INR Lakhs ・Standalone data |
|||||||||||
| Number of Long-term Reagent Rental Contracts Count ・Standalone data |
|||||||||||
| TRUPCR Europe Sales GBP |
|||||||||||
| Installed Capacity Utilization % ・Standalone data |
|||||||||||
| R&D Expenditure (Percentage of Turnover) % ・Standalone data |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Submitted Regulation 74(5) RTA confirmation certificate for quarter ended 30 September 2026.
-
Announcement under Regulation 30 (LODR)-Change in Management
- 54th AGM approved re-appointment of Mrs. Mithla Dubey as director on September 29, 2026.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- Shareholder Meeting / Postal Ballot-Outcome of AGM
-
Closure of Trading Window
- Trading window closed from 1 Oct 2026 until 48 hours after Q2 FY27 results.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Concalls
-
Sep 2026PPT
-
Aug 2026PPT
-
Jun 2026Transcript REC
-
Jun 2026PPT REC
-
Feb 2026Transcript PPT REC
-
Nov 2025PPT
-
Aug 2025Transcript PPT REC
-
May 2025PPT
-
Feb 2025PPT
-
Nov 2024PPT
-
Aug 2024PPT
-
May 2024PPT
-
Feb 2024PPT
-
Nov 2023PPT
-
Aug 2023PPT
-
May 2023PPT
-
Feb 2023PPT
-
Nov 2022PPT
-
Sep 2022PPT
-
Aug 2022PPT
-
May 2022PPT
-
Feb 2022PPT
-
Nov 2021PPT
-
Sep 2021PPT
-
Jul 2021PPT
-
Jun 2021PPT
-
Feb 2021PPT
-
Feb 2021PPT
-
Nov 2020PPT
-
Sep 2020PPT
-
Jul 2020PPT
-
Jun 2020PPT
-
Feb 2020PPT
-
Nov 2019PPT
-
Jul 2019PPT
-
May 2019PPT
-
Jan 2019PPT
-
Nov 2018PPT
-
Aug 2018PPT
-
May 2018PPT
-
Feb 2018PPT
-
Nov 2017PPT
-
Jul 2017PPT
-
Feb 2017PPT
Business Overview: [1][2]
3B BlackBio Dx Ltd, (formerly Kilpest
India Ltd) operates 2 businesses viz.
molecular diagnostics and agrochemicals,
with diagnostics as the primary focus. The diagnostics business designs, develops, manufactures and commercialises qPCR assays, rapid diagnostic tests, NGS based kits, digital PCR assays and nucleic acid extraction solutions across infectious diseases, oncology, genetics and antimicrobial resistance (AMR). The registered office and factory are located at Govindpura, Bhopal.